
According to data from Benzinga Pro, during Q4, ADMA Biologics's (NASDAQ:ADMA) reported sales totaled $26.38 million. Despite a 6.0% increase in earnings, the company posted a loss of $16.65 million. In Q3, ADMA Biologics brought in $20.68 million in sales but lost $17.71 million in earnings.